N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits

Acta Neuropathologica

Volumn 126, Issue 2, 2013, Pages 189-205

  Bouter, Yvonne ^a   Dietrich, Katharina ^a   Wittnam, Jessica L ^a   Rezaei Ghaleh, Nasrollah ^c   Pillot, Thierry ^d   Papot Couturier, Sophie ^d   Lefebvre, Thomas ^d   Sprenger, Frederick ^a   Wirths, Oliver ^a   Zweckstetter, Markus ^b,c   Bayer, Thomas A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^d Synaging SAS   (France)

Author keywords

Degeneration; Neuron loss; Pyroglutamate Abeta; Spatial reference memory; Toxicity; Transgenic mouse model

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[3-42]; AMYLOID BETA PROTEIN[4-38]; AMYLOID BETA PROTEIN[4-42]; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CELL LOSS; CONTROLLED STUDY; CYTOTOXICITY; FIBER; GENOTYPE; HEMIZYGOSITY; HIPPOCAMPAL CA1 REGION; HOMOZYGOSITY; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; PYRAMIDAL NERVE CELL; RAT; SPATIAL MEMORY; WORKING MEMORY;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; FEMALE; FETUS; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR WEIGHT; NERVE DEGENERATION; NEURONS; PREGNANCY; PRIMARY CELL CULTURE; RATS; RATS, WISTAR; SOLUBILITY; SPACE PERCEPTION;

EID: 84881099652     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1129-2     Document Type: Article

References (71)

1. Alexandru A, Jagla W, Graubner S et al (2011) Selective Hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation. J Neurosci 31:12790-12801
2. Barrow CJ, Zagorski MG (1991) Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 253:179-182
3. Benilova I, Karran E, De Strooper B (2012) The toxic A[beta] oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 29:349-357
4. Breyhan H, Wirths O, Duan K, Marcello A, Rettig J, Bayer TA (2009) APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol 117:677-685
5. Broadbent NJ, Squire LR, Clark RE (2004) Spatial memory, recognition memory, and the hippocampus. Proc Natl Acad Sci USA 101:14515-14520
6. Brouillette J, Caillierez R, Zommer N et al (2012) Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci 32:7852-7861
7. Casas C, Sergeant N, Itier JM et al (2004) Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated A{beta}42 accumulation in a novel alzheimer transgenic model. Am J Pathol 165:1289-1300
8. Christensen DZ, Kraus SL, Flohr A, Cotel MC, Wirths O, Bayer TA (2008) Transient intraneuronal Abeta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol 116:647-655
9. Christensen DZ, Bayer TA, Wirths O (2010) Intracellular Abeta triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging 31:1153-1163
10. Cynis H, Schilling S, Bodnar M et al (2006) Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim Biophys Acta 1764:1618-1625
11. Dong J, Atwood CS, Anderson VE et al (2003) Metal binding and oxidation of amyloid-β within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42:2768-2773
12. Glabe CG, Kayed R (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66:S74-S78
13. Güntert A, Dobeli H, Bohrmann B (2006) High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143:461-475
14. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-112
15. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG (2000) Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 276:422-427
16. Harmeier A, Wozny C, Rost BR et al (2009) Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity. J Neurosci 29:7582-7590
17. Haupt C, Leppert J, Ronicke R et al (2012) Structural basis of beta-amyloid-dependent synaptic dysfunctions. Angew Chem Int Ed Engl 51:1576-1579
18. Hosoda R, Saido TC, Otvos L Jr et al (1998) Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J Neuropathol Exp Neurol 57:1089-1095
19. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is Abeta 42(43). Neuron 13:45-53
20. Jawhar S, Wirths O, Bayer TA (2011) Pyroglutamate Abeta - a hatchet man in Alzheimer disease. J Biol Chem 286:38825-38832
21. Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O (2012) Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 33:196 e129-196.e140
22. Kawarabayashi T, Younkin L, Saido T, Shoji M, Ashe K, Younkin S (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372-381
23. Klein WL (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41:345-352
24. Kumar S, Rezaei-Ghaleh N, Terwel D et al (2011) Extracellular phosphorylation of the amyloid [beta]-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO J 30:2255-2265
25. Kumar S, Wirths O, Theil S, Gerth J, Bayer TA, Walter J (2013) Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer's disease. Acta Neuropathol 125:699-709
26. Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE (1998) Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim Biophys Acta 1406:291-298
27. Kuo YM, Kokjohn TA, Beach TG et al (2001) Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276:12991-12998
28. Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453
29. Lambert MP, Velasco PT, Chang L et al (2007) Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 100:23-35
30. Lesne S, Koh MT, Kotilinek L et al (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357
31. Lewis H, Beher D, Cookson N et al (2006) Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-β(42) peptide in vascular dementia. Neuropathol Appl Neurobiol 32:103-118
32. Maeda J, Ji B, Tomiyama T et al (2007) Longitudinal, quantitative assesment of amyloid, neuroinflammation and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by PET. J Neurosci 27:10957-10968
33. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245-4249
34. McLean CA, Cherny RA, Fraser FW et al (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46:860-866
35. Miller DL, Papayannopoulos IA, Styles J et al (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 301:41-52
36. Milton NGN (2001) Phosphorylation of amyloid-[beta] at the serine 26 residue by human cdc2 kinase. NeuroReport 12:3839-3844
37. Mori H, Takio K, Ogawara M, Selkoe DJ (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 267:17082-17086
38. Mori H, Ishii K, Tomiyama T et al (1994) Racemization: its biological significance on neuropathogenesis of Alzheimer's disease. Tohoku J Exp Med 174:251-262
39. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60
40. Moser MB, Moser EI, Forrest E, Andersen P, Morris RG (1995) Spatial learning with a minislab in the dorsal hippocampus. Proc Natl Acad Sci USA 92:9697-9701
41. Näslund J, Schierhorn A, Hellman U et al (1994) Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 91:8378-8382
42. Oakley H, Cole SL, Logan S et al (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129-10140
43. Ono K, Condron MM, Teplow DB (2009) Structure-neurotoxicity relationships of amyloid β-protein oligomers. Proc Natl Acad Sci USA 106:14745-14750
44. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36
45. Pike CJ, Overman MJ, Cotman CW (1995) Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270:23895-23898
46. Pillot T, Drouet B, Queillé S et al (1999) The nonfibrillar amyloid β-peptide induces apoptotic neuronal cell death. J Neurochem 73:1626-1634
47. Portelius E, Bogdanovic N, Gustavsson MK et al (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 120:185-193
48. Prelli F, Castano E, Glenner GG, Frangione B (1988) Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem 51:648-651
49. Renner M, Lacor PN, Velasco PT et al (2010) Deleterious effects of amyloid [beta] oligomers acting as an extracellular scaffold for mGluR5. Neuron 66:739-754
50. Roher A, Lowenson J, Clarke S et al (1993) Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268:3072-3083
51. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284:4749-4753
52. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK (1997) Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett 409:411-416
53. Russo C, Schettini G, Saido TC et al (2000) Presenilin-1 mutations in Alzheimer's disease. Nature 405:531-532
54. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, Abeta N3(pE), in senile plaques. Neuron 14:457-466
55. Sarter M, Bodewitz G, Stephens DN (1988) Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology 94:491-495
56. Schlenzig D, Rönicke R, Cynis H et al (2012) N-terminal pyroglutamate (pGlu) formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal LTP. J Neurochem 121:774-784
57. Schmitz C, Rutten BP, Pielen A et al (2004) Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 164:1495-1502
58. Selkoe DJ (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8:447-453
59. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766
60. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oigomers of the Alzheimer amyloid-{beta} protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:2866-2875
61. Shankar GM, Li S, Mehta TH et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837-842
62. Shimizu T, Matsuoka Y, Shirasawa T (2005) Biological significance of isoaspartate and its repair system. Biol Pharm Bull 28:1590-1596
63. Shin RW, Ogino K, Kondo A et al (1997) Amyloid beta-protein (Abeta) 1-40 but not Abeta1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain. J Neurosci 17:8187-8193
64. Tomiyama T, Asano S, Furiya Y, Shirasawa T, Endo N, Mori H (1994) Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues. J Biol Chem 269:10205-10208
65. Vorhees CV, Williams MT (2006) Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1:848-858
66. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497
67. Wilcox K, Lacor P, Pitt J, Klein W (2011) Aβ oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol 31:939-948
68. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA (2009) Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 118:487-496
69. Wirths O, Bethge T, Marcello A et al (2010) Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 117:85-96
70. Wittnam JL, Portelius E, Zetterberg H et al (2012) Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J Biol Chem 287:8154-8162
71. Youssef I, Florent-Béchard S, Malaplate-Armand C et al (2008) N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. Neurobiol Aging 29:1319-1333